The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

There has been a "dramatic" decrease in cases of RSV among babies due to a new vaccine but flu is rising and expected to peak after Christmas, the interim chief medical officer said. Usually one in ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it. Sobi also ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...

IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...

At a meeting to present its vaccines pipeline to investors today, the French pharma is highlighting the potential of Beyfortus (nirsevimab) for the protection of infants in their first RSV season ...

SummaryState warns of rising COVID threat, surge in Whooping Cough cases The Illinois Department of Public Health is ...

Yesterday, officials in British Columbia (BC) reported a fourth case of chronic wasting disease (CWD) in the Kootenay region ...

The effort to remove President Yoon Suk Yeol reflected fury over his declaration of martial law. He lifted the order within hours after it incited protests. Members of South Korea’s opposition ...